表紙
市場調査レポート

生体吸収性ステント:医療機器のパイプライン評価

Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015

発行 GlobalData 商品コード 347100
出版日 ページ情報 英文 124 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
生体吸収性ステント:医療機器のパイプライン評価 Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015
出版日: 2015年12月01日 ページ情報: 英文 124 Pages
概要

当レポートでは、生体吸収性ステントのパイプライン製品について調査分析し、開発段階別の比較分析に焦点を当てて、パイプライン製品の開発に従事している主要企業、進行中の臨床試験に関する情報なども含めて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 生体吸収性ステントの概要

第3章 開発中の製品

  • 生体吸収性ステント - パイプライン製品:開発段階別
  • 生体吸収性ステント - パイプライン製品:地域別
  • 生体吸収性ステント - パイプライン製品:規制別
  • 生体吸収性ステント - パイプライン製品:承認予定日別
  • 生体吸収性ステント - 進行中の臨床試験

第4章 生体吸収性ステント - 開発中のパイプライン製品:企業別

  • 生体吸収性ステント企業 - パイプライン製品:開発段階別
  • 生体吸収性ステント - パイプライン製品:開発段階別

第5章 生体吸収性ステント企業と製品の概要

  • Abbott Vascular Inc.
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical, Inc.
  • Arterius Ltd
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • HangZhou HuaAn Biotechnology Co., Ltd.
  • Icon Interventional Systems, Inc.
  • 日本ステントテクノロジー
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medlogics Device Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • NanoCoeur, Inc.
  • Northwestern University
  • OrbusNeich
  • REVA Medical, Inc.
  • S3V Vascular Technologies
  • Shanghai MicroPort Medical (Group) Co., Ltd.
  • Tepha, Inc.
  • Terumo Corporation
  • Xenogenics Corporation
  • Zorion Medical

第6章 生体吸収性ステント - 最近の動向

第7章 付録

図表

目次
Product Code: GDME0100EPD

GlobalData's Medical Devices sector report, "Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015" provides an overview of Bioabsorbable Stents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bioabsorbable Stents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Bioabsorbable Stents Overview

3. Products under Development

  • 3.1. Bioabsorbable Stents - Pipeline Products by Stage of Development
  • 3.2. Bioabsorbable Stents - Pipeline Products by Territory
  • 3.3. Bioabsorbable Stents - Pipeline Products by Regulatory Path
  • 3.4. Bioabsorbable Stents - Pipeline Products by Estimated Approval Date
  • 3.5. Bioabsorbable Stents - Ongoing Clinical Trials

4. Bioabsorbable Stents - Pipeline Products under Development by Companies

  • 4.1. Bioabsorbable Stents Companies - Pipeline Products by Stage of Development
  • 4.2. Bioabsorbable Stents - Pipeline Products by Stage of Development

5. Bioabsorbable Stents Companies and Product Overview

  • 5.1. Abbott Vascular Inc. Company Overview
    • 5.1.1. Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. AlviMedica Medical Technologies Inc. Company Overview
    • 5.2.1. AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Amaranth Medical, Inc. Company Overview
    • 5.3.1. Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Arterius Ltd Company Overview
    • 5.4.1. Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Biosensors International Group, Ltd. Company Overview
    • 5.5.1. Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Biotronik SE & Co. KG Company Overview
    • 5.6.1. Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Boston Scientific Corporation Company Overview
    • 5.7.1. Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Cardionovum GmbH Company Overview
    • 5.8.1. Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Elixir Medical Corporation Company Overview
    • 5.9.1. Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
    • 5.10.1. HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Icon Interventional Systems, Inc. Company Overview
    • 5.11.1. Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Japan Stent Technology Co., Ltd. Company Overview
    • 5.12.1. Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Lepu Medical Technology (Beijing) Co., Ltd. Company Overview
    • 5.13.1. Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Medlogics Device Corporation Company Overview
    • 5.14.1. Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Meril Life Sciences Pvt. Ltd. Company Overview
    • 5.15.1. Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. MicroPort Scientific Corporation Company Overview
    • 5.16.1. MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. NanoCoeur, Inc. Company Overview
    • 5.17.1. NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Northwestern University Company Overview
    • 5.18.1. Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. OrbusNeich Company Overview
    • 5.19.1. OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. REVA Medical, Inc. Company Overview
    • 5.20.1. REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. S3V Vascular Technologies Company Overview
    • 5.21.1. S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. Shanghai MicroPort Medical (Group) Co., Ltd. Company Overview
    • 5.22.1. Shanghai MicroPort Medical (Group) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Tepha, Inc. Company Overview
    • 5.23.1. Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Terumo Corporation Company Overview
    • 5.24.1. Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Xenogenics Corporation Company Overview
    • 5.25.1. Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Zorion Medical Company Overview
    • 5.26.1. Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview

6. Bioabsorbable Stents- Recent Developments

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Bioabsorbable Stents - Pipeline Products by Stage of Development
  • Table 2: Bioabsorbable Stents - Pipeline Products by Territory
  • Table 3: Bioabsorbable Stents - Pipeline Products by Regulatory Path
  • Table 4: Bioabsorbable Stents - Pipeline Products by Estimated Approval Date
  • Table 5: Bioabsorbable Stents - Ongoing Clinical Trials
  • Table 6: Bioabsorbable Stents Companies - Pipeline Products by Stage of Development
  • Table 7: Bioabsorbable Stents - Pipeline Products by Stage of Development
  • Table 8: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Absorb Bioresorbable Vascular Scaffold - Product Status
  • Table 10: Absorb Bioresorbable Vascular Scaffold - Product Description
  • Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Status
  • Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Description
  • Table 13: Abbott Vascular Inc. - Ongoing Clinical Trials Overview
  • Table 14: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects with de Novo Native Coronary Artery Lesions in Chinese Population
  • Table 15: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold In The Treatment Of Subjects with De Novo Native Coronary Artery Lesions
  • Table 16: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions
  • Table 17: Absorb Bioresorbable Vascular Scaffold - A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects with Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: ABSORB II Randomized Controlled Trial
  • Table 18: Absorb Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation
  • Table 19: Absorb Bioresorbable Vascular Scaffold - A Multicenter Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)
  • Table 20: Absorb Bioresorbable Vascular Scaffold - A Post-market Registry of Patients with de Novo Lesions in Previously Untreated Vessels Treated with Absorb BVS
  • Table 21: Absorb Bioresorbable Vascular Scaffold - A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus Absorb Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)
  • Table 22: Absorb Bioresorbable Vascular Scaffold - A Randomized Controlled Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention with Bioresorbable Vascular Scaffold
  • Table 23: Absorb Bioresorbable Vascular Scaffold - ABSORB Bioresorbable Scaffold versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis
  • Table 24: Absorb Bioresorbable Vascular Scaffold - Absorb Bioresorbable Scaffold Vs. Drug Coated Balloon for Treatment of In-stent-restenosis
  • Table 25: Absorb Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers
  • Table 26: Absorb Bioresorbable Vascular Scaffold - An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS): ABSORB FIRST Registry
  • Table 27: Absorb Bioresorbable Vascular Scaffold - Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience) in Acute ST-Elevation Myocardial Infarction
  • Table 28: Absorb Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: a Multi-modality, Multi-specialty Collaborative Study (PERFECT Program)
  • Table 29: Absorb Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study
  • Table 30: Absorb Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis
  • Table 31: Absorb Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study
  • Table 32: Absorb Bioresorbable Vascular Scaffold - Optimal Lesion Preparation with Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) - OPRENBIS Study
  • Table 33: Absorb Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)
  • Table 34: Absorb Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)
  • Table 35: AlviMedica Medical Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Coracto Rapamycin-Eluting Coronary Stent - Product Status
  • Table 37: Coracto Rapamycin-Eluting Coronary Stent - Product Description
  • Table 38: Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Status
  • Table 40: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Description
  • Table 41: FORTITUDE Scaffold - Product Status
  • Table 42: FORTITUDE Scaffold - Product Description
  • Table 43: Next Generation FORTITUDE Scaffold - Product Status
  • Table 44: Next Generation FORTITUDE Scaffold - Product Description
  • Table 45: Amaranth Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 46: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
  • Table 47: Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
  • Table 48: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
  • Table 49: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
  • Table 51: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
  • Table 52: Biosensors International Group, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 53: Sparrow Drug Eluting Stent System - Product Status
  • Table 54: Sparrow Drug Eluting Stent System - Product Description
  • Table 55: Biosensors International Group, Ltd. - Ongoing Clinical Trials Overview
  • Table 56: Sparrow Drug Eluting Stent System - CARE II Clinical Trial
  • Table 57: Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 58: DREAMS - Product Status
  • Table 59: DREAMS - Product Description
  • Table 60: DREAMS 2 - Product Status
  • Table 61: DREAMS 2 - Product Description
  • Table 62: Biotronik SE & Co. KG - Ongoing Clinical Trials Overview
  • Table 63: DREAMS 2 - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
  • Table 64: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: Fully Resorbable Drug-Eluting Scaffold System - Product Status
  • Table 66: Fully Resorbable Drug-Eluting Scaffold System - Product Description
  • Table 67: Next Generation SYNERGY - Product Status
  • Table 68: Next Generation SYNERGY - Product Description
  • Table 69: Boston Scientific Corporation - Ongoing Clinical Trials Overview
  • Table 70: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study (FAST)
  • Table 71: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 72: ReNATURAL (M) - Product Status
  • Table 73: ReNATURAL (M) - Product Description
  • Table 74: ReNATURAL (P) - Product Status
  • Table 75: ReNATURAL (P) - Product Description
  • Table 76: RESORB - Product Status
  • Table 77: RESORB - Product Description
  • Table 78: Elixir Medical Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 79: DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • Table 80: DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • Table 81: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • Table 82: DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • Table 83: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
  • Table 84: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
  • Table 85: Elixir Medical Corporation - Ongoing Clinical Trials Overview
  • Table 86: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Post-market Evaluation of Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
  • Table 87: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including "Real World" Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree of Selection Criteria
  • Table 88: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 89: Xinsorb BRS - Product Status
  • Table 90: Xinsorb BRS - Product Description
  • Table 91: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 92: Dissolving Stent - Product Status
  • Table 93: Dissolving Stent - Product Description
  • Table 94: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 95: Bioabsorbable Stent - Product Status
  • Table 96: Bioabsorbable Stent - Product Description
  • Table 97: Lepu Medical Technology (Beijing) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 98: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Status
  • Table 99: NeoVas Bioresorbable Coronary Scaffold (BCS) - Product Description
  • Table 100: Lepu Medical Technology (Beijing) Co., Ltd. - Ongoing Clinical Trials Overview
  • Table 101: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study
  • Table 102: NeoVas Bioresorbable Coronary Scaffold (BCS) - Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients with Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial
  • Table 103: Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 104: COBRA-P Drug Eluting Stent - Product Status
  • Table 105: COBRA-P Drug Eluting Stent - Product Description
  • Table 106: Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 107: BIOMIME AURA - Product Status
  • Table 108: BIOMIME AURA - Product Description
  • Table 109: MeRes - Product Status
  • Table 110: MeRes - Product Description
  • Table 111: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: Firefalcon Bioresorbable Device - Product Status
  • Table 113: Firefalcon Bioresorbable Device - Product Description
  • Table 114: NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: Nanocoating Cardiac Stent - Product Status
  • Table 116: Nanocoating Cardiac Stent - Product Description
  • Table 117: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Liquid Biodegradable Drug Eluting Stent - Product Status
  • Table 119: Liquid Biodegradable Drug Eluting Stent - Product Description
  • Table 120: OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • Table 121: Acute BRS - Product Status
  • Table 122: Acute BRS - Product Description
  • Table 123: Cura Stent - Product Status
  • Table 124: Cura Stent - Product Description
  • Table 125: REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 126: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Status
  • Table 127: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Description
  • Table 128: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
  • Table 129: ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
  • Table 130: ReZolve2 - Product Status
  • Table 131: ReZolve2 - Product Description
  • Table 132: REVA Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 133: Fantom Sirolimus-Eluting Bioresorbable Scaffold - FANTOM I Clinical Trial
  • Table 134: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold
  • Table 135: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II)
  • Table 136: S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 137: 3V Avatar - Product Status
  • Table 138: 3V Avatar - Product Description
  • Table 139: Shanghai MicroPort Medical (Group) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 140: Bioresorbable Scaffold System - Product Status
  • Table 141: Bioresorbable Scaffold System - Product Description
  • Table 142: Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 143: TephaFLEX Absorbable Stent - Product Status
  • Table 144: TephaFLEX Absorbable Stent - Product Description
  • Table 145: Terumo Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 146: Bioresorbable Coronary Stent - Product Status
  • Table 147: Bioresorbable Coronary Stent - Product Description
  • Table 148: Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 149: Ideal BioStent - First Generation - Product Status
  • Table 150: Ideal BioStent - First Generation - Product Description
  • Table 151: Ideal BioStent - Second Generation - Product Status
  • Table 152: Ideal BioStent - Second Generation - Product Description
  • Table 153: Whisper Coronary Stent System - Product Status
  • Table 154: Whisper Coronary Stent System - Product Description
  • Table 155: Zorion Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 156: ZMED Absorbable Drug Eluting Stent - Product Status
  • Table 157: ZMED Absorbable Drug Eluting Stent - Product Description
  • Table 158: Glossary

List of Figures

  • Figure 1: Bioabsorbable Stents - Pipeline Products by Stage of Development
  • Figure 2: Bioabsorbable Stents - Pipeline Products by Territory
  • Figure 3: Bioabsorbable Stents - Pipeline Products by Regulatory Path
  • Figure 4: Bioabsorbable Stents - Pipeline Products by Estimated Approval Date
  • Figure 5: Bioabsorbable Stents - Ongoing Clinical Trials
Back to Top